JP2016518328A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016518328A5 JP2016518328A5 JP2016501667A JP2016501667A JP2016518328A5 JP 2016518328 A5 JP2016518328 A5 JP 2016518328A5 JP 2016501667 A JP2016501667 A JP 2016501667A JP 2016501667 A JP2016501667 A JP 2016501667A JP 2016518328 A5 JP2016518328 A5 JP 2016518328A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- alkoxy
- alkyl
- gene
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361777427P | 2013-03-12 | 2013-03-12 | |
| US61/777,427 | 2013-03-12 | ||
| PCT/US2014/024885 WO2014165232A1 (en) | 2013-03-12 | 2014-03-12 | Compounds for treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016518328A JP2016518328A (ja) | 2016-06-23 |
| JP2016518328A5 true JP2016518328A5 (enExample) | 2017-04-13 |
Family
ID=51659101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016501667A Pending JP2016518328A (ja) | 2013-03-12 | 2014-03-12 | 癌治療のための化合物 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US9713612B2 (enExample) |
| EP (1) | EP2968348A4 (enExample) |
| JP (1) | JP2016518328A (enExample) |
| KR (1) | KR20150125665A (enExample) |
| CN (1) | CN105142641A (enExample) |
| AU (1) | AU2014248568B2 (enExample) |
| CA (1) | CA2905830C (enExample) |
| WO (1) | WO2014165232A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20151261T1 (hr) | 2007-07-02 | 2016-01-01 | Oncomed Pharmaceuticals, Inc. | Sastavi i postupci za lijeäśenje i dijagnosticiranje raka |
| JP6185463B2 (ja) | 2011-07-15 | 2017-08-23 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Ｒｓｐｏ結合剤およびその使用法 |
| US9556144B2 (en) * | 2012-06-15 | 2017-01-31 | Curegenix, Inc. | Compound as WNT signaling inhibitor, composition, and use thereof |
| EA032038B1 (ru) | 2012-07-13 | 2019-03-29 | Онкомед Фармасьютикалс, Инк. | Rspo3-связывающие агенты и их применение |
| CA2905830C (en) | 2013-03-12 | 2022-01-18 | Curegenix Inc. | Quinazoline and naphthyridine derivatives useful in the treatment of cancer |
| CN105348298B (zh) * | 2014-07-04 | 2019-03-19 | 沈阳中化农药化工研发有限公司 | 取代芳基吡啶类化合物及其用途 |
| JP2017528523A (ja) | 2014-09-16 | 2017-09-28 | オンコメッド ファーマシューティカルズ インコーポレイテッド | 線維性疾患の治療 |
| MA41123A (fr) * | 2014-12-02 | 2017-10-10 | Oncomed Pharm Inc | Polythérapie pour le traitement du cancer |
| KR20180010198A (ko) * | 2015-05-26 | 2018-01-30 | 큐어제닉스 코포레이션 | 종양 바이오마커 및 이의 용도 |
| CN107613980A (zh) * | 2015-05-31 | 2018-01-19 | 源生公司 | 用于免疫疗法的组合组合物 |
| GB201516504D0 (en) | 2015-09-17 | 2015-11-04 | Astrazeneca Ab | Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer |
| WO2017062688A1 (en) * | 2015-10-08 | 2017-04-13 | Suzhou Yunxuan Yiyao Keji Youxian Gongsi | Wnt signaling pathway inhibitors and therapeutic applications thereof |
| US10450300B2 (en) | 2015-10-08 | 2019-10-22 | Suzhou Yunxuan Yiyao Keji Youxian Gongsi | Wnt signaling pathway inhibitors and therapeutic applications thereof |
| CN105254613A (zh) * | 2015-10-08 | 2016-01-20 | 苏州云轩医药科技有限公司 | 具有Wnt信号通路抑制活性的杂环化合物及其应用 |
| WO2017095918A2 (en) * | 2015-12-01 | 2017-06-08 | Oncomed Pharmaceuticals, Inc. | Methods for treating cancer using rspo3 antagonists |
| WO2017162611A1 (en) * | 2016-03-21 | 2017-09-28 | Astrazeneca Ab | Quinoline-3-carboxamide compounds and their use in treating cancer |
| WO2017167150A1 (zh) * | 2016-03-31 | 2017-10-05 | 苏州云轩医药科技有限公司 | 一种3-氟吡啶杂环化合物及其应用 |
| KR102476709B1 (ko) | 2016-11-21 | 2022-12-09 | 나노스트링 테크놀로지스, 인크. | 화학적 조성물 및 이것을 사용하는 방법 |
| EP3559264A4 (en) * | 2016-12-21 | 2020-08-12 | Agency for Science, Technology and Research | MALIGNANT DISORDER IDENTIFICATION KIT AND ITS USES |
| BR112019018093A2 (pt) * | 2017-03-30 | 2020-06-16 | F. Hoffmann-La Roche Ag | Compostos, composição, método de inibição de hpk1, métodos para melhorar uma resposta imune e para tratar um distúrbio e usos do composto |
| CN107441045B (zh) | 2017-07-21 | 2018-10-19 | 广州源生医药科技有限公司 | 用于递送Wnt信号通路抑制剂的脂质体制剂及其制备方法 |
| SG11202001684PA (en) | 2017-10-06 | 2020-03-30 | Forma Therapeutics Inc | Inhibiting ubiquitin specific peptidase 30 |
| JP7525402B2 (ja) | 2018-05-14 | 2024-07-30 | ナノストリング テクノロジーズ，インコーポレイティド | 化学的組成物とそれを利用する方法 |
| ES2988920T3 (es) | 2018-05-17 | 2024-11-22 | Forma Therapeutics Inc | Compuestos bicíclicos fusionados útiles como inhibidores de la peptidasa 30 específica de ubiquitina |
| CN108685923A (zh) * | 2018-06-07 | 2018-10-23 | 广州源生医药科技有限公司 | Wnt信号通路抑制剂在治疗LGR5阳性癌症中的应用 |
| US10961534B2 (en) | 2018-07-13 | 2021-03-30 | University of Pittsburgh—of the Commonwealth System of Higher Education | Methods of treating porphyria |
| PL3860989T3 (pl) | 2018-10-05 | 2023-07-10 | Forma Therapeutics, Inc. | Sprzężone piroliny, które działają jako inhibitory proteazy 30 swoistej dla ubikwityny (usp30) |
| US12365686B2 (en) * | 2019-07-08 | 2025-07-22 | Jiangsu Kanion Pharmaceutical Co., Ltd. | Compound as porcupine inhibitor and use thereof |
| CN117088876A (zh) * | 2020-10-28 | 2023-11-21 | 杭州阿诺生物医药科技有限公司 | 一种高活性Wnt通路抑制剂化合物 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999011622A1 (en) * | 1997-09-03 | 1999-03-11 | Guilford Pharmaceuticals Inc. | Amino-substituted compounds, methods, and compositions for inhibiting parp activity |
| ATE552253T1 (de) * | 2002-11-08 | 2012-04-15 | Novartis Int Pharm Ltd | 3-substituierte-6-aryl- pyridin derivate als liganden für c5a-rezeptoren |
| EP2093298A3 (en) * | 2003-10-10 | 2009-09-23 | Deutsches Krebsforschungszentrum | Compositions for diagnosis and therapy of diseases associated with aberrant expression of Futrins (R-Spondins) |
| CA2569404A1 (en) * | 2004-06-04 | 2005-12-22 | Amphora Discovery Corporation | Quinoline- and isoquinoline-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
| RU2007130077A (ru) * | 2005-01-07 | 2009-02-20 | Эмори Юниверсити (Us) | Антагонисты cxcr4 и их применение для лечения вич-инфекции |
| US20090004185A1 (en) * | 2007-01-11 | 2009-01-01 | Wyeth | Amino-substituted quinazoline derivatives as inhibitors of beta-catenin/tcf-4 pathway and cancer treatment agents |
| US8450344B2 (en) | 2008-07-25 | 2013-05-28 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
| UA103918C2 (en) | 2009-03-02 | 2013-12-10 | Айерем Элелси | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators |
| CN102573473B (zh) * | 2009-06-09 | 2015-05-27 | 加利福尼亚资本权益有限责任公司 | 用作hedgehog 信号转导抑制剂的异喹啉、喹啉和喹唑啉衍生物 |
| CN102558173B (zh) | 2010-12-31 | 2015-05-20 | 广州源生医药科技有限公司 | 抑制wnt信号传导的化合物、组合物及其应用 |
| AU2013226323B2 (en) | 2012-02-28 | 2016-07-14 | Irm Llc | Cancer patient selection for administration of Wnt signaling inhibitors using RNF43 mutation status |
| US9556144B2 (en) | 2012-06-15 | 2017-01-31 | Curegenix, Inc. | Compound as WNT signaling inhibitor, composition, and use thereof |
| CA2905830C (en) | 2013-03-12 | 2022-01-18 | Curegenix Inc. | Quinazoline and naphthyridine derivatives useful in the treatment of cancer |
| KR20180010198A (ko) | 2015-05-26 | 2018-01-30 | 큐어제닉스 코포레이션 | 종양 바이오마커 및 이의 용도 |
-
2014
- 2014-03-12 CA CA2905830A patent/CA2905830C/en active Active
- 2014-03-12 AU AU2014248568A patent/AU2014248568B2/en not_active Ceased
- 2014-03-12 CN CN201480013734.1A patent/CN105142641A/zh active Pending
- 2014-03-12 KR KR1020157024496A patent/KR20150125665A/ko not_active Withdrawn
- 2014-03-12 JP JP2016501667A patent/JP2016518328A/ja active Pending
- 2014-03-12 EP EP14778108.2A patent/EP2968348A4/en not_active Withdrawn
- 2014-03-12 WO PCT/US2014/024885 patent/WO2014165232A1/en not_active Ceased
- 2014-03-12 US US14/772,337 patent/US9713612B2/en active Active
-
2017
- 2017-06-08 US US15/617,988 patent/US10238652B2/en active Active
-
2019
- 2019-01-29 US US16/261,353 patent/US10660889B2/en active Active